DE68915812D1 - Funktionspezifische Antikörper. - Google Patents

Funktionspezifische Antikörper.

Info

Publication number
DE68915812D1
DE68915812D1 DE68915812T DE68915812T DE68915812D1 DE 68915812 D1 DE68915812 D1 DE 68915812D1 DE 68915812 T DE68915812 T DE 68915812T DE 68915812 T DE68915812 T DE 68915812T DE 68915812 D1 DE68915812 D1 DE 68915812D1
Authority
DE
Germany
Prior art keywords
target cells
function
specific antibodies
active agent
attached
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68915812T
Other languages
English (en)
Other versions
DE68915812T2 (de
Inventor
Paul G Abrams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poniard Pharmaceuticals Inc
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Publication of DE68915812D1 publication Critical patent/DE68915812D1/de
Application granted granted Critical
Publication of DE68915812T2 publication Critical patent/DE68915812T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1054—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE68915812T 1988-02-26 1989-02-24 Funktionspezifische Antikörper. Expired - Lifetime DE68915812T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/160,648 US4867962A (en) 1988-02-26 1988-02-26 Functionally specific antibodies

Publications (2)

Publication Number Publication Date
DE68915812D1 true DE68915812D1 (de) 1994-07-14
DE68915812T2 DE68915812T2 (de) 1994-12-22

Family

ID=22577787

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68915812T Expired - Lifetime DE68915812T2 (de) 1988-02-26 1989-02-24 Funktionspezifische Antikörper.

Country Status (7)

Country Link
US (1) US4867962A (de)
EP (1) EP0331034B1 (de)
JP (1) JPH0749377B2 (de)
AT (1) ATE106750T1 (de)
AU (1) AU621347B2 (de)
CA (1) CA1340409C (de)
DE (1) DE68915812T2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017648A (en) * 1986-05-30 1991-05-21 La Jolla Pharmaceutical Company D-GL conjugate therapy
US4950469A (en) * 1986-05-30 1990-08-21 La Jolla Pharmaceutical Company D-GL conjugate therapy
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US6051405A (en) * 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US4965392A (en) * 1987-03-26 1990-10-23 Neorx Corporation Chelating compounds for metal-radionuclide labeled proteins
US5112954A (en) * 1988-02-26 1992-05-12 Neorx Corporation Method of enhancing the effect of cytotoxic agents
US4988496A (en) * 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
EP0436664B1 (de) * 1988-09-30 1994-11-09 Neorx Corporation Spaltbare linker zur reduzierung der akkumulierung von immunokonjugaten in nicht-zielorganen
US5171563A (en) * 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
JPH0829101B2 (ja) * 1989-04-21 1996-03-27 アメリカ合衆国 組換え抗体―毒素融合タンパク質
ZA914625B (en) * 1990-06-22 1993-02-24 Lilly Co Eli In vivo targeting with bifunctional antibodies
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US5889157A (en) 1990-10-12 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Humanized B3 antibody fragments, fusion proteins, and uses thereof
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
WO1993024135A1 (en) * 1992-05-26 1993-12-09 Immunex Corporation Novel cytokine that binds cd30
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US5976535A (en) * 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
JPH08504172A (ja) * 1992-06-30 1996-05-07 オンコロジクス，インコーポレイティド 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
US5756825A (en) * 1992-09-08 1998-05-26 Safavy; Ahmad Hydroxamic acid-based bifunctional chelating compounds
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
EP0733066B1 (de) * 1993-12-07 2003-11-19 NeoRx Corporation Pretargeting verfahren und mitteln
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
IL140700A0 (en) 1998-07-13 2002-02-10 Univ Texas Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
AU771224B2 (en) 1998-07-13 2004-03-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
WO2005119025A2 (en) 2004-06-01 2005-12-15 Spectrum Dynamics Llc Radioactive-emission-measurement optimization to specific body structures
US8489176B1 (en) 2000-08-21 2013-07-16 Spectrum Dynamics Llc Radioactive emission detector equipped with a position tracking system and utilization thereof with medical systems and in medical procedures
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
JP2004535202A (ja) 2001-07-17 2004-11-25 リサーチ　ディベロップメント　ファンデーション アポトーシス促進性蛋白質を含む治療剤
KR20050038005A (ko) 2002-07-18 2005-04-25 헬릭스 바이오파마 코포레이션 암세포 성장의 저해를 위한 우레아제의 사용
EP1572242B1 (de) 2002-12-13 2014-04-16 Immunomedics, Inc. Immun-conjugate mit einem intrazellular spaltbaren linker
US8420086B2 (en) * 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
WO2006051531A2 (en) 2004-11-09 2006-05-18 Spectrum Dynamics Llc Radioimaging
US7968851B2 (en) 2004-01-13 2011-06-28 Spectrum Dynamics Llc Dynamic spect camera
US8586932B2 (en) 2004-11-09 2013-11-19 Spectrum Dynamics Llc System and method for radioactive emission measurement
WO2007010534A2 (en) 2005-07-19 2007-01-25 Spectrum Dynamics Llc Imaging protocols
US8571881B2 (en) 2004-11-09 2013-10-29 Spectrum Dynamics, Llc Radiopharmaceutical dispensing, administration, and imaging
US9040016B2 (en) 2004-01-13 2015-05-26 Biosensors International Group, Ltd. Diagnostic kit and methods for radioimaging myocardial perfusion
CN1981210A (zh) 2004-01-13 2007-06-13 光谱动力学有限责任公司 多维图像重构
US9470801B2 (en) 2004-01-13 2016-10-18 Spectrum Dynamics Llc Gating with anatomically varying durations
US8000773B2 (en) 2004-11-09 2011-08-16 Spectrum Dynamics Llc Radioimaging
US9316743B2 (en) 2004-11-09 2016-04-19 Biosensors International Group, Ltd. System and method for radioactive emission measurement
US8615405B2 (en) 2004-11-09 2013-12-24 Biosensors International Group, Ltd. Imaging system customization using data from radiopharmaceutical-associated data carrier
US9943274B2 (en) 2004-11-09 2018-04-17 Spectrum Dynamics Medical Limited Radioimaging using low dose isotope
WO2008059489A2 (en) 2006-11-13 2008-05-22 Spectrum Dynamics Llc Radioimaging applications of and novel formulations of teboroxime
US8837793B2 (en) 2005-07-19 2014-09-16 Biosensors International Group, Ltd. Reconstruction stabilizer and active vision
US8041409B2 (en) * 2005-09-08 2011-10-18 Carestream Health, Inc. Method and apparatus for multi-modal imaging
US8894974B2 (en) * 2006-05-11 2014-11-25 Spectrum Dynamics Llc Radiopharmaceuticals for diagnosis and therapy
US20100143935A1 (en) * 2006-12-01 2010-06-10 Apocell, Inc. c-KIT Phosphorylation in Cancer
WO2008075362A2 (en) 2006-12-20 2008-06-26 Spectrum Dynamics Llc A method, a system, and an apparatus for using and processing multidimensional data
JP2010518942A (ja) * 2007-02-22 2010-06-03 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド 不安定プラークまたは動脈瘤のような脆弱化した血管壁の治療
US8521253B2 (en) 2007-10-29 2013-08-27 Spectrum Dynamics Llc Prostate imaging
US8318398B2 (en) * 2009-02-06 2012-11-27 Xerox Corporation Toner compositions and processes
US8338788B2 (en) 2009-07-29 2012-12-25 Spectrum Dynamics Llc Method and system of optimized volumetric imaging
CA2782194C (en) * 2009-12-02 2018-01-16 Immunomedics, Inc. Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
BR112017015582A2 (pt) 2015-01-23 2018-03-13 Helix Biopharma Corp conjugados de anticorpo-urease para propósitos terapêuticos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311688A (en) * 1979-10-29 1982-01-19 Serono Laboratories Inc. Composition and method for cancer detection in humans
AU556548B2 (en) * 1980-03-03 1986-11-06 Milton David Goldenberg Tumor localization and therapy with labeled antibodies and antibody fragments specific to tumor-associated markers
AT392004B (de) * 1981-10-27 1991-01-10 Hybritech Inc Verfahren zur herstellung eines monoklonalen antikoerpers gegen tumor-assoziiertes antigen und dessen verwendung
US4444740A (en) * 1983-02-14 1984-04-24 Atlantic Richfield Company Method for the recovery of fluorides from spent aluminum potlining and the production of an environmentally safe waste residue
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
ATE61000T1 (de) * 1983-07-29 1991-03-15 Milton David Goldenberg Verfahren zur erhoehung der zielspezifizitaet in antikoerperbestimmungen und zur raeumung von nichtzielspezifischen diagnostischen und therapeutischen faktoren.
EP0222360A3 (de) * 1985-11-12 1989-03-15 Biotherapeutics Inc. Verfahren zur Herstellung von einem patientspezifischen zytotoxischen Reagenz und Zubereitung

Also Published As

Publication number Publication date
ATE106750T1 (de) 1994-06-15
EP0331034A2 (de) 1989-09-06
US4867962A (en) 1989-09-19
EP0331034A3 (en) 1990-07-25
JPH0749377B2 (ja) 1995-05-31
AU3075389A (en) 1989-08-31
JPH01316329A (ja) 1989-12-21
DE68915812T2 (de) 1994-12-22
EP0331034B1 (de) 1994-06-08
AU621347B2 (en) 1992-03-12
CA1340409C (en) 1999-02-23

Similar Documents

Publication Publication Date Title
DE68915812T2 (de) Funktionspezifische Antikörper.
NL300351I1 (nl) Geneesmiddelen met monoclonale antilichamen, die specifiek zijn voor de menselijk epidermale groeifactorreceptor
FI864037A0 (fi) Monoklonala antikroppar mot broestkraefta hos maenniska.
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
DK79390D0 (da) Anti-leukocytkonjugat og anvendelse heraf
ES2124209T3 (es) Anticuerpos monoclonales mejorados reactivos con caquectina.
EP0330201A3 (de) Methode zur Verbesserung der Aktivität von cytotoxischen Verbindungen
DE59611341D1 (de) Verwendung von saccharid-konjugaten
ES2152216T3 (es) Usos terapeuticos de la region hipervariable del anticuerpo monoclonal m195 y constructos de la misma.
DK0552296T3 (da) Monoklonale antistoffer fra mus
DE3686313D1 (de) Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.
DK0525119T3 (da) Antistofkonjugater til behandling af neoplastisk sygdom
FI853389L (fi) Tumoerlaekemedel och foerfarande foer dess framstaellning.
ATE362377T1 (de) Therapeutische konjugate die die vaskuläre glatten muskelzellen inhibitieren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee